Saturday, March 2, 2024

CATEGORY

Johnson & Johnson

Expanding Horizons in Multiple Myeloma Treatment: CHMP Backs Earlier Application of Carvykti CAR-T Therapy

European drug regulators have given their endorsement for Johnson & Johnson (J&J) and Legend Biotech’s Carvykti to be used earlier in the multiple myeloma...

Treatment of LA or Metastatic Bladder Cancer BALVERSA® Fully Approved by FDA

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for BALVERSA® (erdafitinib)...

Johnson & Johnson’s TAR-200 Granted FDA Breakthrough Status for High-Risk Bladder Cancer

Johnson & Johnson received FDA Breakthrough Therapy Designation (BTD) for TAR-200, a promising treatment for high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients unsuitable for radical...

Regulatory Approval Granted for MONARCH Bronchoscopy Platform in China

Johnson & Johnson MedTech has announced that its MONARCH Platform and MONARCH Bronchoscope have received regulatory approval in China, making it the first minimally...

Sanofi Successfully Concludes Development for Innovative Extraintestinal Pathogenic E. Coli Vaccine

Sanofi has successfully concluded the closing of its collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to jointly develop and market a...

Sanofi Achieves Milestone: Closes Potential First-in-Class Vaccine for Extraintestinal Pathogenic E.coli

Sanofi has successfully concluded the closure of its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, marking a significant step...

TREMFYA® Demonstrates Significant Patient-Reported Outcomes in Psoriatic Arthritis

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has unveiled promising data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry. This real-world study...

Janssen Submits SIRTURO® Study Results for Pulmonary Tuberculosis to EMA and FDA

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II Variation application to the European Medicines Agency (EMA) and a supplemental...

A Study Confirms Mechanism of Action for Nipocalimab in Moderate to Severe Rheumatoid Arthritis

The Janssen Pharmaceutical Companies of Johnson & Johnson have released data from the Phase 2a IRIS-RA clinical study, demonstrating the effectiveness of nipocalimab in...

RYBREVANT® Plus Chemotherapy Significantly Reduces Disease Progression in EGFR-Mutated Lung Cancer

In a groundbreaking development, the Janssen Pharmaceutical Companies of Johnson & Johnson have unveiled results from the Phase 3 MARIPOSA-2 study indicating that the...

Latest news

Sticky Image